Home Featured Page 127

Featured

Latest

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine

Usona Files Psilocybin for Depression NDA as Race With Compass Tightens

Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted...

Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on...

PT400 – Beckley Retreats: Combining Modern Science, Tradition, and Holistic Wellness

Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in...

Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

Algernon Pharmaceuticals Announces Launch of Rights Offering

Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration...

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine...

Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT...

EDITOR PICKS

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House...

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic...

Compass Says NDA Will Be Filed Within Two Weeks, Declines to...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.